Aurobindo Pharma Buyback 2024 vs Indus Towers Buyback 2024

The Buy-Back is being undertaken, inter-alia, for the following reasons:

1. The buy-back will help the company reward its shareholders and enhance the overall return to shareholders.
2. The buy-back is expected to improve earnings per share and other key ratios such as return on net worth and return on assets over a period of time;
3. The buy-back is being implemented through the tender offer route as prescribed under the buyback regulations and would involve the allocation of the number of equity shares as per their entitlement or 15% of the number of equity shares to be bought back, whichever is higher, reserved for small shareholders.

The Buyback is being undertaken, inter-alia, for the following reasons:

• The current Buyback is in line with the Company's Shareholder-friendly capital allocation practices of enhancing overall Shareholders' value, thereby improving earnings per Share, and optimizing returns to Shareholders.
• The Buyback, which is being implemented through the Tender Offer route as prescribed under the Buyback Regulations, would involve allocation of number of Equity Shares as per their entitlement or 15% (fifteen percent) of the number of Equity Shares to be bought back, whichever is higher, reserved for Small Shareholders. The Company believes that this reservation for Small Shareholders would benefit a large number of public Shareholders, who would get classified as "small shareholders" as per Regulation 2(i)(n) of the Buyback Regulations.
• The Buyback gives the Eligible Shareholders the choice to either:
  • participate in the Buyback and receive cash in lieu of their Equity Shares which are accepted under the Buyback; or
  • not to participate in the Buyback and get a resultant increase in their percentage shareholding in the Company post the Buyback, without additional investment.